OncoGenex Prices Secondary Offering, Shares Fall (OGXI)

Photo of Paul Ausick
By Paul Ausick Published

Invalid Image
Cancer therapy developer OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI) has priced a secondary offering of 4.165 million common shares at $12.00/share, a discount of 31% to yesterday’s closing price of $17.43. Needless to say the shares are getting pounded today.

OncoGenex expects to realize about $46.8 million from the offering, net of fees and expenses. Leerink Swann LLC and Stifel Nicolaus Weisel are acting as joint book-running managers and Lazard Capital Markets LLC and William Blair & Company, L.L.C. are acting as co-managers. The underwriters have a 30-day over-allotment option of 624,750 shares.

The company did not specify how it plans to use the proceeds from the sale.

Shares are down nearly -20% at $13.99 in a 52-week range of $8.63-$18.99.

Contact [email protected] for any questions or corrections.

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

ABNB Vol: 15,913,532
MCHP Vol: 19,139,274
PLTR Vol: 77,244,625
MRNA Vol: 6,820,582
AXON Vol: 1,591,869

Top Losing Stocks

TTD Vol: 133,458,224
CTRA Vol: 73,319,495
AKAM Vol: 8,143,961
ZTS Vol: 12,784,553
RMD Vol: 3,810,438